Phase II Trial of Cisplatin, Etoposide, and 5-Fluorouracil in Advanced Non–Small-Cell Lung Cancer: An Eastern Cooperative Oncology Group Study (PB586)
O Kucuk, DH Shevrin, KJ Pandya… - American journal of …, 2000 - journals.lww.com
Advanced non–small-cell lung cancer (NSCLC) remains an incurable disease despite
significant progress in chemotherapy. We conducted a phase II clinical trial to investigate the
efficacy and toxicity of a cisplatin, etoposide, and 5-fluorouracil (5-FU) combination in
advanced metastatic and/or recurrent NSCLC. Forty patients with advanced, recurrent, or
metastatic, measurable NSCLC were treated with cisplatin, 60 mg/m 2 intravenously (iv) on
day 1; etoposide, 120 mg/m 2/day iv on days 1, 2, and 3; and 5-FU, 1,000 mg/m 2/day iv …
significant progress in chemotherapy. We conducted a phase II clinical trial to investigate the
efficacy and toxicity of a cisplatin, etoposide, and 5-fluorouracil (5-FU) combination in
advanced metastatic and/or recurrent NSCLC. Forty patients with advanced, recurrent, or
metastatic, measurable NSCLC were treated with cisplatin, 60 mg/m 2 intravenously (iv) on
day 1; etoposide, 120 mg/m 2/day iv on days 1, 2, and 3; and 5-FU, 1,000 mg/m 2/day iv …